Skip to main content

Table 1 Characteristics of study subjects

From: Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal

 

Normal control (n = 27)

Episodic migraine (n = 99)

Chronic migraine (n = 44)

P-value

Age

34 (27–42)

44 (31–49)

39.5 (31–54)

0.016

Female sex

25 (92.6%)

78 (78.8%)

36 (81.8%)

0.258

Migraine with aura

NA

18 (18.2%)

8 (18.2%)

> 0.999

Headache days/month

NA

5 (2–10)

27 (15–30)

< 0.001

Hypertension

0 (0%)

6 (6.06%)

5 (11.36%)

0.162

Diabetes

0 (0%)

0 (0%)

1 (2.27%)

0.237

Dyslipidemia

0 (0%)

6 (6.06%)

5 (11.36%)

0.162

Stroke

0 (0%)

1 (1.01%)

1 (2.27%)

0.670

Cardiac disease

0 (0%)

2 (2.02%)

2 (4.55%)

0.445

Current smoking

0 (0%)

6 (6.06%)

5 (11.36%)

0.162

Fibromyalgia

0 (0%)

1 (1.01%)

2 (4.55%)

0.250

Depression

0 (0%)

4 (4.04%)

12 (27.27%)

< 0.001

Anxiety disorder

0 (0%)

1 (1.01%)

8 (18.18%)

< 0.001

Panic disorder

0 (0%)

2 (2.02%)

3 (6.82%)

0.180

Preventive medication

0 (0%)

19 (19.19%)

22 (50%)

< 0.001

 TCA

0 (0%)

13 (13.13%)

18 (40.91%)

< 0.001

 Beta-blocker

0 (0%)

15 (15.15%)

15 (34.09%)

0.001

 CCB

0 (0%)

12 (12.12%)

13 (29.55%)

0.002

 Antiepileptic drugs

0 (0%)

3 (3.03%)

11 (25%)

< 0.001

 ARB

0 (0%)

2 (2.02%)

1 (2.27%)

0.745

  1. NA = not assessed; TCA = tricyclic antidepressant; CCB = calcium-channel blocker; ARB = angiotensin-II receptor blocker